Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

17.44 +0.51 (+3.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Why This Acadia Pharmaceuticals Move Has Analysts Split — And Shares Down 20%
After a rejection in April, Acadia is planning to ask for approval in Alzheimer's patients. 
Via Investor's Business Daily
The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers ACADIA Pharmaceuticals (NASDAQ:ACAD 
Via Benzinga
Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Top Biotech Stocks: Trading Opportunities For Next Week
A security pattern traces the distinct movements of prices, which helps traders make informed trading decisions. Let's look at some biotech stock opportunities by analyzing these patterns. 
Via Talk Markets
Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer
From Acadia Pharmaceuticals Inc.
Via Business Wire
What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
Over the past 3 months, 7 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ: 
Via Benzinga
Why Acadia Pharmaceuticals Stock Is Rocketing Today
A positive clinical readout is lighting a fire underneath the biotech's shares today. 
Via The Motley Fool
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers ACADIA Pharmaceuticals (NASDAQ:ACAD) stock rose 18.35% to $22.96 during Tuesday's pre-market session. The company's market cap stands at $3.6 billion.... 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Oppenheimer cut the price target on Coupa Software Incorporated (NASDAQ: 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, trader! We're beginning another busy day of trading with a breakdown of the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
22 Stocks Moving in Tuesday's Pre-Market Session
Gainers Bluejay Diagnostics, Inc. (NASDAQ: BJDX) rose 23.7% to $3.18 in pre-market trading after jumping 10% on Monday. The company, last month, priced its IPO at $10 per unit.... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Acadia Pharma Jumps After Rett Syndrome Candidate Aces Phase 3 Study
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced topline results from Phase 3 Lavender study of trofinetide in Rett syndrome. The 12-week study demonstrated a... 
Via Benzinga
Acadia Pharmaceuticals Stock Sprints After Rett Syndrome Drug Scores A Testing Win
The drug showed improvements across multiple measures of Rett syndrome. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers ACADIA Pharmaceuticals (NASDAQ:ACAD 
Via Benzinga
Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of Schizophrenia
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals and StoryCorps Collaborate to Launch Yours, Truly – a Multicultural Storytelling Campaign to Bring Greater Awareness to Parkinson’s Disease Non-Motor Symptoms
From Acadia Pharmaceuticals Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Frequency Therapeutics (NASDAQ:FREQ) stock rose 10.94% to $7.51 during Tuesday's regular session. The current volume of 277.7K shares is 160.43% of Frequency... 
Via Benzinga
Acadia Pharmaceuticals Inc (ACAD) Q3 2021 Earnings Call Transcript
ACAD earnings call for the period ending November 8, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
ACADIA Pharmaceuticals: Q3 Earnings Insights
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q3 earnings results on Monday, November 8, 2021 at 04:05 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results
From Acadia Pharmaceuticals Inc.
Via Business Wire
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data at Psych Congress 2021
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial
From Acadia Pharmaceuticals Inc.
Via Business Wire
Where ACADIA Pharmaceuticals Stands With Analysts
Over the past 3 months, 5 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ: 
Via Benzinga
Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Present Data on Pimavanserin in Patients with Parkinson’s Disease Dementia with Psychosis from the HARMONY trial at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX: 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.